Dovato Tablet, Film Coated
Product Images NDC 49702-246

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Dovato (NDC 49702-246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dolutegravir Sodium Structural Formula (Dovato Spl Graphic 01)

Chemical structure of the active ingredients dolutegravir sodium and lamivudine, as featured in the antiretroviral drug Dovato by ViiV Healthcare Company.*

FDA Label Image

Lamivudine Structural Formula (Dovato Spl Graphic 02)

Chemical structure diagram showing the molecular configuration of dolutegravir sodium and lamivudine, the active ingredients in Dovato tablets. The structure features ring and chain components indicative of the compounds.*

FDA Label Image

Dovato 30 Count Label (Dovato Spl Graphic 03)

Dovato 50 mg/300 mg film-coated tablets packaging label showing the proprietary name Dovato and generic names dolutegravir and lamivudine. The label states the tablet strength as 50 mg dolutegravir and 300 mg lamivudine, with a package count of 30 tablets. It includes storage information, manufacturer details (ViiV Healthcare Company), and a QR code, along with precautionary notes and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.